AU2018278311B2 - IRE1 small molecule inhibitors - Google Patents

IRE1 small molecule inhibitors Download PDF

Info

Publication number
AU2018278311B2
AU2018278311B2 AU2018278311A AU2018278311A AU2018278311B2 AU 2018278311 B2 AU2018278311 B2 AU 2018278311B2 AU 2018278311 A AU2018278311 A AU 2018278311A AU 2018278311 A AU2018278311 A AU 2018278311A AU 2018278311 B2 AU2018278311 B2 AU 2018278311B2
Authority
AU
Australia
Prior art keywords
optionally substituted
amino
aminocyclohexyl
compound
chlorobenzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018278311A
Other languages
English (en)
Other versions
AU2018278311A1 (en
Inventor
Sarah Bettigole
Dansu Li
Joseph P. Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of AU2018278311A1 publication Critical patent/AU2018278311A1/en
Assigned to CORNELL UNIVERSITY reassignment CORNELL UNIVERSITY Request for Assignment Assignors: QUENTIS THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2018278311B2 publication Critical patent/AU2018278311B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018278311A 2017-06-01 2018-05-31 IRE1 small molecule inhibitors Ceased AU2018278311B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513929P 2017-06-01 2017-06-01
US62/513,929 2017-06-01
PCT/US2018/035465 WO2018222918A1 (en) 2017-06-01 2018-05-31 Ire1 small molecule inhibitors

Publications (2)

Publication Number Publication Date
AU2018278311A1 AU2018278311A1 (en) 2019-12-12
AU2018278311B2 true AU2018278311B2 (en) 2021-10-07

Family

ID=64455585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018278311A Ceased AU2018278311B2 (en) 2017-06-01 2018-05-31 IRE1 small molecule inhibitors

Country Status (6)

Country Link
US (3) US20180346446A1 (https=)
EP (1) EP3630748B1 (https=)
JP (1) JP7126084B2 (https=)
AU (1) AU2018278311B2 (https=)
CA (1) CA3064837A1 (https=)
WO (1) WO2018222918A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649224B2 (en) 2017-06-01 2023-05-16 Cornell University IRE1 small molecule inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS
WO2019094641A1 (en) * 2017-11-10 2019-05-16 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
US12071426B2 (en) 2018-12-03 2024-08-27 Cornell University IRE1 small molecule inhibitors
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
AR118119A1 (es) * 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
BR112021016974A2 (pt) * 2019-02-27 2021-11-30 Optikira Llc Compostos de pirazolopiridina para inibição de ire1
WO2020232403A1 (en) * 2019-05-15 2020-11-19 Cornell University Treatment of fibrosis with ire1 small molecule inhibitors
WO2020232401A1 (en) * 2019-05-15 2020-11-19 Cornell University Combination therapies with ire1 small molecule inhibitors
EP3983400B1 (en) * 2019-06-11 2025-05-28 Genentech, Inc. Quinazolinyl compounds and methods of use
CA3159578A1 (en) * 2019-11-01 2021-05-06 Janssen Biotech, Inc. Fluorinated quinoline and quinoxaline derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases
US20240262830A1 (en) * 2020-02-03 2024-08-08 Nimbus Iaso, Inc. Ire1a modulators and uses thereof
JP2023514328A (ja) * 2020-02-17 2023-04-05 アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ Ｇｃｎ２モジュレーター化合物
WO2022032078A1 (en) * 2020-08-07 2022-02-10 Optikira, LLC Pyrazolopyridine compounds and methods of inhibiting ire1 using same
US11840523B2 (en) * 2020-11-13 2023-12-12 The Regents Of The University Of California IRE1α inhibitors and uses thereof
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
WO2024131893A1 (en) * 2022-12-22 2024-06-27 Shanghai Yi Zhong Xing Biotechnology Co., Ltd. IRE1α SMALL MOLECULE INHIBITORS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US20150158874A1 (en) * 2011-03-17 2015-06-11 Cmg Pharmaceutical Co., Ltd. Novel pyridopyrimidine derivatives and use thereof
US20150190466A1 (en) * 2013-12-20 2015-07-09 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254169B1 (en) 1999-12-30 2007-05-09 President And Fellows of Harvard College Methods relating to modulation of th2 cell subset activity by modulation of xbp-1 activity
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
US8017331B2 (en) 2005-11-04 2011-09-13 Mannkind Corporation IRE-1α substrates
CA2638734A1 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
US8940479B2 (en) 2008-01-14 2015-01-27 Cornell University Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CN103079558B (zh) * 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2014176348A1 (en) 2013-04-23 2014-10-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
WO2017152126A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
AR111281A1 (es) 2017-03-17 2019-06-26 Genentech Inc Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
WO2019094641A1 (en) * 2017-11-10 2019-05-16 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US20150158874A1 (en) * 2011-03-17 2015-06-11 Cmg Pharmaceutical Co., Ltd. Novel pyridopyrimidine derivatives and use thereof
US20150190466A1 (en) * 2013-12-20 2015-07-09 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG, W. et al., "3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors", Journal of Molecular Structure, (2013), vol. 1054-105, pages 107 - 116 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649224B2 (en) 2017-06-01 2023-05-16 Cornell University IRE1 small molecule inhibitors

Also Published As

Publication number Publication date
JP7126084B2 (ja) 2022-08-26
EP3630748A1 (en) 2020-04-08
CA3064837A1 (en) 2018-12-06
US20210284628A1 (en) 2021-09-16
US20200157079A1 (en) 2020-05-21
JP2020522520A (ja) 2020-07-30
AU2018278311A1 (en) 2019-12-12
US20180346446A1 (en) 2018-12-06
US11649224B2 (en) 2023-05-16
US11021466B2 (en) 2021-06-01
EP3630748B1 (en) 2023-04-19
EP3630748A4 (en) 2021-01-27
WO2018222918A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
AU2018278311B2 (en) IRE1 small molecule inhibitors
US20240425477A1 (en) Ire1 small molecule inhibitors
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP6898868B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
KR20080109095A (ko) Ｆｇｆ 수용체 키나제 억제제를 위한 조성물 및 방법
WO2018222917A1 (en) Ire1 small molecule inhibitors
WO2020038460A1 (zh) 一种新型的喹啉衍生物抑制剂
US12479818B2 (en) Treatment of fibrosis with IRE1 small molecule inhibitors
CN110997657A (zh) 咪唑烷化合物
EP4445901A2 (en) New potent and selective compounds as serotonin 1b receptor modulators
EP4201924B1 (en) Ire1 small molecule inhibitors
CN112912142B (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
US20200055871A1 (en) Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
HK1185067A (en) Hetarylaminonaphthyridines

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CORNELL UNIVERSITY

Free format text: FORMER APPLICANT(S): QUENTIS THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired